Agios Pharmaceuticals Stock News

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios Pharmaceuticals, Inc.''s (NASDAQ: AGIO ) Pyrukynd (mitapivat) was approved for the treatment of hemolytic anemia in people with pyruvate kinase deficiency. Hemolysis refers to the destruction of red blood cells. Pyrukynd is a "new molecular entity," a term that refers to a drug containing an active moiety that hasn''t been previously approved by the FDA. NME approval, therefore, is considered a measure of innovation in drug research. Another NME that passed the FDA hurdle was Sanofi''s (NASDAQ: SNY ) Enjaymo for the treatment of hemolysis in adults with cold agglutinin disease. Reata Pharmaceuticals, Inc. (NASDAQ: RETA ), as expected, received a complete response letter for its new drug application for bardoxolone methyl as a treatment option for Alport syndrome. An Adcom that met in early December voted against recommending approval of the drug.

AGIO, ALIM, and BV have been added to the Zacks Rank #5 (Strong Sell) List on March 1, 2022

AGIO, ALIM, and BV have been added to the Zacks Rank #5 (Strong Sell) List on March 1, 2022

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, to

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, toda

Agios Pharmaceuticals (AGIO) posts wider-than-expected loss for the fourth quarter of 2021. It does not record any revenues in the quarter.

Within the last quarter, Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 1 0 0

Agios Pharmaceuticals (AGIO) posts wider-than-expected loss for the fourth quarter of 2021. It does not record any revenues in the quarter.

Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.

Agios Pharmaceuticals, Inc. (AGIO) CEO Jackie Fouse on Q4 2021 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced th

Agios Pharmaceuticals press release (AGIO): Q4 GAAP EPS of -$1.81 misses by $0.12.Cash, cash equivalents and marketable securities as of Dec

– Received FDA Approval of PYRUKYND® (mitapivat) for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) Deficiency; First Approved Therapy for this Rare Blood Disorder –